From: The Hill
Executives at Eli Lilly, one of the nation’s largest pharmaceutical companies, are denouncing the Trump administration’s proposal to consider ways to import prescription drugs from other countries.
***
Azar has said he thinks rebates give an incentive for higher drug prices, since both the PBM and drug company get a cut. A proposal that would remove certain legal protections around rebates is currently under review by the White House Office of Management and Budget.